With 30-year industry chops, Pamela Conley launches a protein therapeutics biotech for autoimmune diseases

Kyle LaHucik

Senior Reporter

After about 17 years at Portola Pharmaceuticals, Pamela Conley was ready for her next venture once helping transition some of the drugmaker’s programs into Alexion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With 30-year industry chops, Pamela Conley launches a protein therapeutics biotech for autoimmune diseases

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

BeiGene will rebrand to BeOne Medicines, dropping name's link to China roots

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

GSK makes case for Blenrep's return with new blood cancer survival data

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

With 30-year in­dus­try chops, Pamela Con­ley launch­es a pro­tein ther­a­peu­tics biotech for au­toim­mune dis­eases

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

With 30-year industry chops, Pamela Conley launches a protein therapeutics biotech for autoimmune diseases

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

BeiGene will rebrand to BeOne Medicines, dropping name's link to China roots

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

GSK makes case for Blenrep's return with new blood cancer survival data

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?